1. Home
  2. VTRS vs KVYO Comparison

VTRS vs KVYO Comparison

Compare VTRS & KVYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTRS
  • KVYO
  • Stock Information
  • Founded
  • VTRS 1961
  • KVYO 2012
  • Country
  • VTRS United States
  • KVYO United States
  • Employees
  • VTRS N/A
  • KVYO N/A
  • Industry
  • VTRS Medicinal Chemicals and Botanical Products
  • KVYO
  • Sector
  • VTRS Health Care
  • KVYO
  • Exchange
  • VTRS Nasdaq
  • KVYO Nasdaq
  • Market Cap
  • VTRS 11.1B
  • KVYO 9.5B
  • IPO Year
  • VTRS N/A
  • KVYO 2023
  • Fundamental
  • Price
  • VTRS $10.19
  • KVYO $25.90
  • Analyst Decision
  • VTRS Hold
  • KVYO Strong Buy
  • Analyst Count
  • VTRS 5
  • KVYO 23
  • Target Price
  • VTRS $10.40
  • KVYO $44.00
  • AVG Volume (30 Days)
  • VTRS 11.7M
  • KVYO 3.7M
  • Earning Date
  • VTRS 11-06-2025
  • KVYO 11-05-2025
  • Dividend Yield
  • VTRS 4.71%
  • KVYO N/A
  • EPS Growth
  • VTRS N/A
  • KVYO N/A
  • EPS
  • VTRS N/A
  • KVYO N/A
  • Revenue
  • VTRS $14,115,700,000.00
  • KVYO $1,078,202,000.00
  • Revenue This Year
  • VTRS N/A
  • KVYO $30.57
  • Revenue Next Year
  • VTRS $1.69
  • KVYO $21.32
  • P/E Ratio
  • VTRS N/A
  • KVYO N/A
  • Revenue Growth
  • VTRS N/A
  • KVYO 33.17
  • 52 Week Low
  • VTRS $6.85
  • KVYO $23.77
  • 52 Week High
  • VTRS $13.55
  • KVYO $49.55
  • Technical
  • Relative Strength Index (RSI)
  • VTRS 57.64
  • KVYO 29.02
  • Support Level
  • VTRS $9.47
  • KVYO $25.85
  • Resistance Level
  • VTRS $10.09
  • KVYO $36.23
  • Average True Range (ATR)
  • VTRS 0.25
  • KVYO 1.66
  • MACD
  • VTRS 0.04
  • KVYO -0.96
  • Stochastic Oscillator
  • VTRS 80.21
  • KVYO 2.82

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

About KVYO Klaviyo Inc. Series A

Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.

Share on Social Networks: